DK0897983T3 - Antistoffer mod CD40-L - Google Patents

Antistoffer mod CD40-L

Info

Publication number
DK0897983T3
DK0897983T3 DK98113461T DK98113461T DK0897983T3 DK 0897983 T3 DK0897983 T3 DK 0897983T3 DK 98113461 T DK98113461 T DK 98113461T DK 98113461 T DK98113461 T DK 98113461T DK 0897983 T3 DK0897983 T3 DK 0897983T3
Authority
DK
Denmark
Prior art keywords
antibodies
immunogen
disclosed
isolated antibody
antibody immunoreactive
Prior art date
Application number
DK98113461T
Other languages
Danish (da)
English (en)
Inventor
Richard J Armitage
William C Fanslow
Melanie K Springs
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27120174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0897983(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK0897983T3 publication Critical patent/DK0897983T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK98113461T 1991-10-25 1992-10-23 Antistoffer mod CD40-L DK0897983T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78370791A 1991-10-25 1991-10-25
US80572391A 1991-12-05 1991-12-05

Publications (1)

Publication Number Publication Date
DK0897983T3 true DK0897983T3 (da) 2003-08-11

Family

ID=27120174

Family Applications (3)

Application Number Title Priority Date Filing Date
DK98113461T DK0897983T3 (da) 1991-10-25 1992-10-23 Antistoffer mod CD40-L
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
DK92925017T DK0667901T4 (da) 1991-10-25 1992-10-23 Hidtil ukendt cytokin

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK97117514T DK0822199T3 (da) 1991-10-25 1992-10-23 N-terminalt monopegylerede polypeptider og fremgangsmåder til fremstilling heraf
DK92925017T DK0667901T4 (da) 1991-10-25 1992-10-23 Hidtil ukendt cytokin

Country Status (12)

Country Link
EP (2) EP0667901B2 (enExample)
JP (2) JP3308534B2 (enExample)
KR (1) KR100283541B1 (enExample)
AT (2) ATE239790T1 (enExample)
AU (1) AU661360B2 (enExample)
CA (2) CA2312667C (enExample)
DE (2) DE69233402T3 (enExample)
DK (3) DK0897983T3 (enExample)
ES (2) ES2198025T3 (enExample)
FI (2) FI116850B (enExample)
NO (2) NO317625B1 (enExample)
WO (1) WO1993008207A1 (enExample)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5716805A (en) * 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US7070777B1 (en) * 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US6472510B1 (en) 1992-02-14 2002-10-29 Bristol-Myers Squibb Company CD40 receptor ligands
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
EP0679191B1 (en) * 1993-01-22 2003-12-10 Immunex Corporation Detection and treatment of mutations in a cd40 ligand gene
DE69423806T2 (de) * 1993-01-22 2000-08-17 Kanegafuchi Chemical Ind Therapeutisches Agens für NIDDM
CN1137726C (zh) * 1993-09-02 2004-02-11 达特茅斯学院理事 延长体液免疫抑制的方法
NZ549136A (en) 1993-09-02 2008-02-29 Dartmouth College Products for inducing antigen-specific T cell tolerance
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ZA946765B (en) 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
AU1059095A (en) * 1993-11-24 1995-06-13 Australian National University, The Treatment of viral disease with cd40l peptide
AU680102B2 (en) * 1993-12-23 1997-07-17 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
ATE309267T1 (de) 1994-04-28 2005-11-15 Boehringer Ingelheim Pharma Methode zur proliferation und differenzierung von b-zellen und verwendungen dafür
KR19980702490A (ko) * 1995-03-01 1998-07-15 스티븐 엘. 말라스카 면역 반응의 자극 방법
WO1996028568A1 (en) 1995-03-13 1996-09-19 The Regents Of The University Of Michigan Cd40 binding compositions and methods of using same
JP3279573B2 (ja) * 1995-06-07 2002-04-30 イミュネックス・コーポレーション 新規の変異型ｃｄ４０ｌ
ES2202455T3 (es) * 1995-06-22 2004-04-01 Biogen, Inc. Cristales de fragmentos del ligando cd40 y su uso.
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
JP2000512541A (ja) * 1996-06-14 2000-09-26 ユニバーシティ オブ ワシントン 吸収力が向上した差違抽出装置
US6017527A (en) * 1996-07-10 2000-01-25 Immunex Corporation Activated dendritic cells and methods for their activation
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
EP2003203A1 (en) 1996-12-23 2008-12-17 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of TNF superfamily
PT2009025E (pt) 1998-05-14 2011-09-19 Immunex Corp Método de inibição da actividade dos osteoclastos
ATE348163T1 (de) * 1998-10-23 2007-01-15 Amgen Inc Thrombopoietin substitute
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
WO2000063395A1 (en) * 1999-04-16 2000-10-26 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
EP1067194A1 (en) * 1999-04-16 2001-01-10 F. Hoffmann-La Roche Ag Vectors containing a gene coding for CD40 and/or CD40L under the control of a cytokine-inducible promoter which is a human acute phase amyloid A gene promoter. Methods for their production and uses thereof
US6482411B1 (en) 1999-08-27 2002-11-19 Board Of Regents, The University Of Texas System Methods of reducing bone loss with CD40 ligand
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU6158501A (en) 2000-05-12 2001-11-26 Beth Israel Hospital Compositions and methods for achieving immune suppression
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
WO2002036769A2 (en) * 2000-10-31 2002-05-10 F. Hoffmann-La Roche Ag Nucleic acids encoding cd40/cd40l chimeric polypeptides, methods for their production and uses thereof
PH12012502439A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
US6586245B2 (en) 2001-07-18 2003-07-01 Isis Pharmaceuticals, Inc. Antisense modulation of CD40 ligand expression
WO2003011324A1 (en) * 2001-07-31 2003-02-13 Genset S.A. Agonists and antagonists of moxifin for the treatment of metabolic disorders
MXPA04002489A (es) 2001-09-20 2004-11-22 Immunex Corp Seleccion de celulas que expresan polipeptidos heteromericos.
US7786282B2 (en) 2001-12-06 2010-08-31 The Regents Of The University Of California Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
US7495090B2 (en) 2002-05-23 2009-02-24 The Regents Of The University Of California Nucleic acids encoding chimeric CD154 polypeptides
CA2515481A1 (en) 2003-02-14 2004-09-02 Biogen Idec Ma Inc. An expression cassette and vector for transient or stable expression of exogenous molecules
EA014226B1 (ru) 2004-07-26 2010-10-29 Байоджен Айдек Ма Инк. Антитела к cd154, их фрагменты и способы применения антител и фрагментов
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
WO2006042177A2 (en) 2004-10-07 2006-04-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
RU2007118954A (ru) 2004-10-22 2008-11-27 Эмджен Инк. (Us) Способ рефолдинга рекомбинантных антител
EP2500414A1 (en) 2006-09-13 2012-09-19 Abbott Laboratories Cell culture improvements
CN103276033A (zh) 2006-09-13 2013-09-04 雅培制药有限公司 细胞培养改良
EP2857038B1 (en) 2006-09-18 2019-04-10 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses
JP5963341B2 (ja) 2007-09-14 2016-08-10 アムジエン・インコーポレーテツド 均質な抗体集団
EP2214840B1 (en) 2007-10-30 2015-05-06 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
CN101970655B (zh) 2008-01-15 2014-03-05 Abbvie公司 改良哺乳动物表达载体及其用途
PL2501822T3 (pl) 2009-11-17 2017-12-29 E. R. Squibb & Sons, L.L.C. Sposoby zwiększenia produkcji białek
US8956618B2 (en) 2010-01-21 2015-02-17 The Texas A&M University System Vaccine vectors and methods of enhancing immune responses
NZ718006A (en) 2010-06-09 2017-06-30 Univ Arkansas Vaccine and methods to reduce campylobacter infection
KR102228324B1 (ko) 2013-02-14 2021-03-15 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 에이메리아에 대한 면역 반응을 증진시키거나, 에이메리아 감염을 제한하는 조성물 및 방법
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
EP3943098A3 (en) 2015-07-16 2022-05-11 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
CN107921128B (zh) 2015-08-05 2022-04-26 詹森生物科技公司 抗cd154抗体及其使用方法
WO2017083604A1 (en) 2015-11-12 2017-05-18 Amgen Inc. Triazine mediated pharmacokinetic enhancement of therapeutics
CA3023144A1 (en) 2016-05-03 2017-11-09 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
ES2914118T3 (es) 2016-05-11 2022-06-07 Amgen Inc Selección directa de células que expresan niveles altos de proteínas heterodiméricas usando vectores de complementación intragénica de glutamina sintetasa
AU2018223822A1 (en) * 2017-02-27 2019-07-11 Shattuck Labs, Inc. CSF1R-based chimeric proteins
EP3585425A4 (en) 2017-02-27 2020-10-28 Shattuck Labs, Inc. PROCESSES FOR THE MANUFACTURE AND USE OF CHEMERICAL PROTEINS BASED ON EXTRACELLULAR DOMAIN

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation

Also Published As

Publication number Publication date
HK1019343A1 (en) 2000-02-03
JPH10150994A (ja) 1998-06-09
CA2312667A1 (en) 1993-04-29
NO941422L (enExample) 1994-06-27
DE69233051D1 (de) 2003-06-12
EP0667901A1 (en) 1995-08-23
EP0667901B2 (en) 2008-10-15
FI981765L (fi) 1998-08-17
NO317625B1 (no) 2004-11-29
NO320073B1 (no) 2005-10-17
EP0897983A2 (en) 1999-02-24
FI941837A0 (fi) 1994-04-20
AU661360B2 (en) 1995-07-20
DE69233402T3 (de) 2009-06-25
AU3122693A (en) 1993-05-21
JPH07504083A (ja) 1995-05-11
CA2312667C (en) 2002-11-19
FI116850B (fi) 2006-03-15
DK0667901T3 (da) 2004-12-27
EP0667901A4 (en) 1995-06-22
CA2121798C (en) 2007-07-24
ES2227513T5 (es) 2009-04-01
JP2877788B2 (ja) 1999-03-31
ES2198025T3 (es) 2004-01-16
DE69233051T2 (de) 2004-03-11
JP3308534B2 (ja) 2002-07-29
WO1993008207A1 (en) 1993-04-29
FI941837L (fi) 1994-05-30
EP0897983B1 (en) 2003-05-07
NO941422D0 (no) 1994-04-19
NO980030D0 (no) 1998-01-05
EP0897983A3 (en) 1999-03-17
DE69233402D1 (de) 2004-09-23
KR100283541B1 (ko) 2001-03-02
FI116828B (fi) 2006-03-15
ATE274055T1 (de) 2004-09-15
ES2227513T3 (es) 2005-04-01
DK0822199T3 (da) 2004-12-27
NO980030L (no) 1998-01-05
EP0667901B1 (en) 2004-08-18
DE69233402T2 (de) 2005-09-15
CA2121798A1 (en) 1993-04-29
DK0667901T4 (da) 2008-11-10
ATE239790T1 (de) 2003-05-15
FI981765A0 (fi) 1998-08-17

Similar Documents

Publication Publication Date Title
DK0897983T3 (da) Antistoffer mod CD40-L
NO891080D0 (no) Undertrykksles av b-celler i pattedyr.
DE3685004D1 (de) Intraokulare linse.
DK666389A (da) Monoklonalt antistof
DE68916079D1 (de) Intraokulare Linse.
DE68914244D1 (de) Monoklonaler Antikörper.
DE3879452D1 (de) Chimaere antikoerper.
DE3850528D1 (de) Intraokulare Linse.
DE68900533D1 (de) Optischer positionssensor.
DE68917796D1 (de) Intraokulare Linse.
FI895287A7 (fi) Fukosyylikeramidin vastainen monoklonaalinen vasta-aine
FI904087A0 (fi) Monoklonala antikroppar mot aktiverade ras-proteiner med aminosyramutationer i position 13 i proteinet.
DE3765979D1 (de) Intraokulare linse mit verminderter blendwirkung.
DK49291A (da) Gramnegativ-bakterieendotoxinblokerende, monoklonale antistoffer
NO890116D0 (no) Monoklonale antistoffer.
DK474189A (da) Monoklonalt antistof
DE68910956D1 (de) Mit toxin modifizierter antikörper.
ATE83930T1 (de) Antikoerper enthaltende stabilisierte waesserige zusammensetzung.
FI893928A7 (fi) Monoklonala motkroppar.
DE3768771D1 (de) Faltbare intraokulare linse.
DE3874403D1 (de) Lichtventil-projektor mit erhoehter lichtausbeute.
NO910287D0 (no) Flerfokal intraokulaer linse.
DE3890354T1 (de) Synthetisches polypeptid mit grippevirus-antigenreaktivitaet
DK594189A (da) Anti-hcg-antistoffer
ATE87031T1 (de) Chimaere antikoerper.